ALBANY, N.Y., March 10, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that they have signed an agreement with Merz North America, U.S. affiliate of the global Merz Pharma Group, to serve as the exclusive distributor of Asclera® (polidocanol) Injection within the vein market in the U.S.
Asclera is approved for the treatment of uncomplicated spider and uncomplicated reticular (small varicose) veins. In a multicenter, randomized, double-blind, placebo and comparator-controlled trial in patients with spider or reticular varicose veins, 95 percent of patients treated with Asclera showed good improvement or complete treatment success as rated by physicians and 87 percent of patients were satisfied or very satisfied with their Asclera treatment1.
"At AngioDynamics, we believe that Asclera represents the future of sclerotherapy vein treatment. Asclera offers a unique benefit for patient care," said Joseph M. DeVivo, President and CEO of AngioDynamics. "As a single-dose treatment, Asclera is an effective treatment option that
simplifies the delivery of patient care for our vein customers. We are excited to partner with health care providers to ensure patients have access to this safe, effective vein treatment option and continue to provide even more value to our vein customers as part of our overall venous disease treatment plan."
"We see this as a significant strategic partnership furthering treatment access for patients who desire to treat and improve the appearance of uncomplicated spider and uncomplicated reticular veins," said Jim Hartman, US Head of Merz Aesthetics Injectables Division. "AngioDynamics is the pre-eminent leader in vein care in the U.S. and has the organization, sales force and existing relationships to capitalize on this opportunity with the goal of reaching more physicians and inevitably
Asclera adds to AngioDynamics' venous disease treatment options which include the market-leading VenaCure EVLT endovenous laser vein treatment system. The Merz partnership replaces previous distribution agreements.
About the Merz North America
Merz North America is a specialty healthcare company that is dedicated to delivering a better total experience in aesthetics, dermatology and neurosciences. As part of the Merz Pharma Group, our ambition is to become the most admired, trusted and innovative aesthetics and neurotoxin company. By developing products that improve patients' health and help them to live better, feel
better and look better, we will continue to make significant contributions to the well-being of individuals around the world. Merz North America is a privately-held company based in Raleigh, North Carolina.
AngioDynamics, Inc. is a leading provider of innovative medical devices used by healthcare professionals for the minimally invasive treatment of cancer and peripheral vascular disease. The Company offers market-leading ablation systems, vascular access products, angiographic products and accessories, dialysis products, drainage products, thrombolytic products, embolization
products and venous products. More information is available at www.angiodynamics.com.
AngioDynamics, the AngioDynamics logo, and VenaCure EVLT are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary. Asclera is a registered trademark of Chemische Fabrik Kreussler & Co. GmbH. Sotradecol is a registered trademark of Mylan Pharma Group Limited.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics'
expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation,
challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2015 and its quarterly
report on Form 10-Q for the fiscal period ended August 31, 2015 and November 30, 2015. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
1 Weiss, Voigts, Howell (2011) Absence of Concentration Congruity in Six Compounded Polidocanol Samples Obtained for Leg Sclerotherapy. American Society for Dermatologic Surgery, Inc., Volume 37: 1-4
AngioDynamics, Inc.Caitlin Stefanik
Investor Relations Contacts:
EVC Group, Inc.Doug Sherk; Chris Dailey
EVC Group, Inc.Dave Schemelia
News Provided by Acquire Media